Contributions

  • Louis M. Aledort (Editor) - Contributor
  • Leon W. Hoyer (Editor) - Contributor
  • Jeanne M. Lusher (Editor) - Contributor
  • Howard M. Reisner (Editor) - Contributor
  • Gilbert C. White II (Editor) - Contributor

Publication

1996-02-29 - Springer

Language

English

Word Count

81,000 words, Guess

Page Count

324 pages

Physical Format

Hardcover

Identifiers

and 3 more

Classifications

  • LCCQP93.5 .I484 1995

Description

The proceeding papers investigate the integration of modern concepts of immunology and hematology toward the design of potential new therapies for the prevention or elimination of antibodies to F.VIII and F.IX. The current research anticipates gene therapy for hemophilias and the implications of inhibitors in such a course of treatment. Papers include discussions on: the molecular and antigenic structure of factors VIII and IX and von Willebrand factor, the human immune response molecular basis, genetic variation and the immune response, inhibitor treatment, coagulation tolerance, and panel discussions.

First Sentence

Ultimately, understanding how inhibitors to coagulation factors develop will require precise knowledge of the structural epitopes in these factors that are recognized by components of the immune system.

Subjects

Other Editions

  • Inhibitors to Coagulation Factors (Advances in Experimental Medicine and Biology)HardcoverSpringer1996-02-29

Reader Reviews

No reviews yet for this book.

Be the first to share your thoughts!